APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease

被引：28

作者：

Beckerman, Pazit ^{[1
,2
,3
]}

Susztak, Katalin ^{[1
,2
]}

机构：

[1] Univ Penn, Perelman Sch Med, Dept Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA

[2] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA

[3] Sheba Med Ctr, Inst Nephrol & Hypertens, Tel Hashomer, Israel

来源：

TRENDS IN MOLECULAR MEDICINE | 2018年 / 24卷 / 08期

关键词：

TRYPANOSOME LYTIC FACTOR; STAGE RENAL-DISEASE; RESISTANCE-ASSOCIATED PROTEIN; LIPID-BINDING PROTEIN; RISK VARIANTS; APOLIPOPROTEIN L1; AFRICAN TRYPANOSOMES; FUNCTION DECLINE; INNATE IMMUNITY; GENE VARIANTS;

D O I：

10.1016/j.molmed.2018.05.008

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Chronic kidney disease (CKD) affects millions of people and constitutes a major health and financial burden worldwide. People of African descent are at an increased risk of developing kidney disease, which is mostly explained by two variants in the Apolipoprotein L1 (APOL1) gene that are found only in people of west African origin. It is hypothesized that these variants were genetically selected due to the protection they afford against African sleeping sickness, caused by the parasite Trypanosoma brucei. Targeting mutant APOL1 could have substantial therapeutic potential for treating kidney disease. In this review, we will describe the intriguing interplay between microbiology, genetics, and kidney disease as revealed in APOL1-associated kidney disease, discuss APOL1-induced cytotoxicity and its therapeutic implications.

引用

页码：682 / 695

页数：14

共 50 条

[1] APOL1 and Kidney Disease: From Genetics to Biology
Friedman, David J.
Pollak, Martin R.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 82, 2020, 82 : 323 - 342
[2] Kidney disease and APOL1
Yusuf, Aminu Abba
Govender, Melanie A.
Brandenburg, Jean-Tristan
Winkler, Cheryl A.
HUMAN MOLECULAR GENETICS, 2021, 30 (R1) : R129 - R137
[3] APOL1 and kidney cell function
Kumar, Vinod
Singhal, Pravin C.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2019, 317 (02) : F463 - F477
[4] APOL1 Kidney Disease Risk Variants: An Evolving Landscape
Dummer, Patrick D.
Limou, Sophie
Rosenberg, Avi Z.
Heymann, Jurgen
Nelson, George
Winkler, Cheryl A.
Kopp, Jeffrey B.
SEMINARS IN NEPHROLOGY, 2015, 35 (03) : 222 - 236
[5] APOL1 and kidney disease
Pollak, Martin R.
Genovese, Giulio
Friedman, David J.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2012, 21 (02) : 179 - 182
[6] Balancing the genetic risk of APOL1 kidney disease variants
Kabore, Nongodo Firmin
Limou, Sophie
NEPHROLOGIE & THERAPEUTIQUE, 2019, 15 : S79 - S84
[7] APOL1 Localization in Normal Kidney and Nondiabetic Kidney Disease
Madhavan, Sethu M.
O'Toole, John F.
Konieczkowski, Martha
Ganesan, Santhi
Bruggeman, Leslie A.
Sedor, John R.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 22 (11): : 2119 - 2128
[8] A focus on the association of Apol1 with kidney disease in children
Ekulu, Pepe M.
Nkoy, Agathe B.
Adebayo, Oyindamola C.
Kazadi, Orly K.
Aloni, Michel N.
Arcolino, Fanny O.
Ngiyulu, Rene M.
Gini, Jean-Lambert E.
Lepira, Francois B.
van den Heuvel, Lamberthus P.
Levtchenko, Elena N.
PEDIATRIC NEPHROLOGY, 2021, 36 (04) : 777 - 788
[9] APOL1 polymorphisms and kidney disease: loss-of-function or gain-of-function?
Bruggeman, Leslie A.
O'Toole, John F.
Sedor, John R.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2019, 316 (01) : F1 - F8
[10] APOL1 and Kidney Disease: New Insights Leading to Novel Therapies
Freedman, Barry I.
AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 66 (01) : 9 - 11

← 1 2 3 4 5 →